Peptide & GLP-1 compounding status tracker
Where the FDA and the states stand on compounding the peptides and GLP-1s med spas ask about — 503A bulks-list status, PCAC reviews, and state overlays. Each standing links to its government source; where only trade-press reporting exists so far, we mark it reported until the FDA primary record posts.
All 12 sources last scanned Sep 9, 2026
Most recent recorded status change Jul 23, 2026 · 49 days ago
8 substances below are before PCAC. A PCAC recommendation does not permit compounding: FDA is not bound, and Category 1 placement — the event that would allow 503A compounding — requires notice-and-comment rulemaking (commonly 8–12 months). Until then these remain not compoundable under 503A.
FDA has announced a further Pharmacy Compounding Advisory Committee meeting before the end of February 2027 to review five more peptides for the 503A Bulks List — GHK-Cu, Melanotan II, LL-37, Dihexa, and PEG-MGF (nominations FDA withdrew in April 2026). The exact date is not yet posted. FDA PCAC ↗
| Substance | Class | Current federal standing | Last change | Source |
|---|---|---|---|---|
| Liraglutide | GLP-1 | On FDA’s 503B clinical-need list — under review | Jun 26, 2026 | doc ↗ |
| Semaglutide | GLP-1 | On FDA’s 503B clinical-need list — under review | Jun 26, 2026 | doc ↗ |
| Tirzepatide | GLP-1 | On FDA’s 503B clinical-need list — under review | Jun 26, 2026 | doc ↗ |
| BPC-157 | Peptide | Under review — not compoundablePCAC recommended listing, 8–6–1 — advisory, FDA not bound | Jul 23, 2026 | doc ↗reported |
| CJC-1295 | Peptide | Under review — not compoundable | Oct 25, 2024 | doc ↗ |
| Dihexa | Peptide | Not compoundable · PCAC review scheduled — by end of Feb 2027 | Feb 2027 (sched.) | — |
| Emideltide | Peptide | Under review — not compoundable | Apr 16, 2026 | doc ↗ |
| Epitalon | Peptide | Under review — not compoundable | Apr 16, 2026 | doc ↗ |
| GHK-CuCopper tripeptide-1 | Peptide | Not compoundable · PCAC review scheduled — by end of Feb 2027 | Feb 2027 (sched.) | — |
| KPV | Peptide | Under review — not compoundablePCAC recommended listing, 8–6–1 — advisory, FDA not bound | Jul 23, 2026 | doc ↗reported |
| LL-37Cathelicidin | Peptide | Not compoundable · PCAC review scheduled — by end of Feb 2027 | Feb 2027 (sched.) | — |
| Melanotan II | Peptide | Not compoundable · PCAC review scheduled — by end of Feb 2027 | Feb 2027 (sched.) | — |
| MOTS-c | Peptide | Under review — not compoundablePCAC recommended listing, 7–5–2 — advisory, FDA not bound | Jul 23, 2026 | doc ↗reported |
| PEG-MGF | Peptide | Not compoundable · PCAC review scheduled — by end of Feb 2027 | Feb 2027 (sched.) | — |
| Semax | Peptide | Under review — not compoundable | Apr 16, 2026 | doc ↗ |
| TB-500Thymosin beta-4 | Peptide | Under review — not compoundablePCAC recommended listing, 8–6–1 — advisory, FDA not bound | Jul 23, 2026 | doc ↗reported |
| BotoxonabotulinumtoxinA | Neurotoxin | Monitoring — no published change yet | — | — |
How a substance gets on the list →
The 503A pathway end to end — nomination, PCAC review, and the rulemaking that has to follow before anything changes in law.
The February 2027 PCAC review →
The five peptides FDA has scheduled for further review, and what a recommendation would and would not change.
Get the change the moment it lands
The free weekly Brief flags FDA and state moves on peptide & GLP-1 compounding — with the source and the date. Members are alerted for their states as soon as a change is published.
Get the free Brief →Informational monitoring compiled from public government sources — not legal or medical advice. No efficacy claims. Verify against the primary source and your own counsel before acting.